Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, ...

The latest announcement is out from Alkermes ( (ALKS) ).

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome ...

Narcolepsy is a neurological disorder that affects your sleep-wake cycle. We still don’t know what causes the condition. But most people with type 1 narcolepsy -- the kind with sudden muscle weakness, ...

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1, based ...

Narcolepsy can be described as a neurological condition that has chronic consequences on the regulation of the sleep-wake ...

Taylor Leamey wrote about all things wellness for CNET, specializing in mental health, sleep and nutrition coverage. She has invested hundreds of hours into studying and researching sleep and holds a ...

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...

Narcolepsy disrupts nighttime sleep and causes attacks of sleepiness, and sometimes muscle weakness, during the day. With a condition that can interfere with your life in so many ways, you’ll want to ...

Narcolepsy is a neurological condition that affects the sleep-wake cycle, so you feel an overwhelming urge to fall asleep at odd times of the day and night. Sleep apnea involves breathing pauses ...